CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
In this registry it is planned to include all Belgian patients diagnosed with aggressive and
symptomatic unresectable locally advanced or metastatic Medullary Thyroid Cancer (MTC) who
have been prescribed Caprelsa® (vandetanib).
The characteristics of patients receiving Caprelsa® (vandetanib) will be described. Therefore
real life data regarding demographic characteristics, evolution of the disease, RET mutation
status, the treatment before, during and after vandetanib, dose and duration of treatment
with Caprelsa® (vandetanib) and time of progression or death (if applicable) will be
included.